China SXT Pharmaceuticals Inc. [NASDAQ: SXTC] slipped around -0.05 points on Monday, while shares priced at $0.70 at the close of the session, down -6.67%. The company report on November 7, 2022 that China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency.
The notification received has no immediate effect on the listing of the Company’s ordinary shares on Nasdaq. Under the Nasdaq Listing Rules, the Company has until May 2, 2023, to regain compliance. If at any time during such 180-day period the closing bid price of the Company’s ordinary shares is at least $1 for a minimum of 10 consecutive business days, Nasdaq will provide the Company written confirmation of compliance.
China SXT Pharmaceuticals Inc. stock is now -94.62% down from its year-to-date (YTD) trading value. SXTC Stock saw the intraday high of $0.92 and lowest of $0.6602 per share. The company’s 52-week high price is 15.80, which means current price is +34.33% above from all time high which was touched on 01/14/22.
Compared to the average trading volume of 175.93K shares, SXTC reached a trading volume of 8330034 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about China SXT Pharmaceuticals Inc. [SXTC]?
The Average True Range (ATR) for China SXT Pharmaceuticals Inc. is set at 0.09, with the Price to Sales ratio for SXTC stock in the period of the last 12 months amounting to 0.90. The Price to Book ratio for the last quarter was 0.06, with the Price to Cash per share for the same quarter was set at 4.65. Price to Free Cash Flow for SXTC in the course of the last twelve months was 7.77 with Quick ratio for the last quarter at 1.30.
How has SXTC stock performed recently?
China SXT Pharmaceuticals Inc. [SXTC] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 13.91. With this latest performance, SXTC shares gained by 21.25% in over the last four-week period, additionally sinking by -61.54% over the last 6 months – not to mention a drop of -93.94% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SXTC stock in for the last two-week period is set at 54.17, with the RSI for the last a single of trading hit 58.34, and the three-weeks RSI is set at 49.45 for China SXT Pharmaceuticals Inc. [SXTC]. The present Moving Average for the last 50 days of trading for this stock 0.6813, while it was recorded at 0.6946 for the last single week of trading, and 2.1300 for the last 200 days.
China SXT Pharmaceuticals Inc. [SXTC]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and China SXT Pharmaceuticals Inc. [SXTC] shares currently have an operating margin of -199.43 and a Gross Margin at +48.10. China SXT Pharmaceuticals Inc.’s Net Margin is presently recorded at -220.43.
Return on Equity for this stock declined to -35.42, with Return on Assets sitting at -16.85.
China SXT Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.30 and a Current Ratio set at 1.30.
Insider trade positions for China SXT Pharmaceuticals Inc. [SXTC]
There are presently around $0 million, or 6.00% of SXTC stock, in the hands of institutional investors. The top three institutional holders of SXTC stocks are: MILLENNIUM MANAGEMENT LLC with ownership of 45,685, which is approximately New of the company’s market cap and around 8.50% of the total institutional ownership; RENAISSANCE TECHNOLOGIES LLC, holding 21,572 shares of the stock with an approximate value of $15000.0 in SXTC stocks shares; and HRT FINANCIAL LP, currently with $8000.0 in SXTC stock with ownership of nearly New of the company’s market capitalization.
4 institutional holders increased their position in China SXT Pharmaceuticals Inc. [NASDAQ:SXTC] by around 64,430 shares. Additionally, 3 investors decreased positions by around 22,781 shares, while 0 investors held positions by with 1,059 shares. The mentioned changes placed institutional holdings at 86,152 shares, according to the latest SEC report filing. SXTC stock had 3 new institutional investments in for a total of 64,280 shares, while 2 institutional investors sold positions of 14,881 shares during the same period.